Skip to main content

Tepnel Raises $2.25M in Stock Offering to Help Pay for Scottish Consolidation

NEW YORK, June 2 (GenomeWeb News) - Tepnel Life Sciences has raised £1.2 million ($2.3 million) in a stock offering, the UK-based company said today.

The funds will be used as "working capital" and also to complete the company's new 18,000-square-foot facility in Livingston, Scotland. The new facility will consolidate operations in Edinburgh and Glasgow and incorporate pharmaceutical services including high throughput genotyping and protein analysis.

The company placed 17,034,160 new ordinary shares priced at 7p apiece with institutional shareholders. In addition, the company has given its investors warrantes to buy as many as 4.3 million additional shares. Tepnel expects stands to gain approximately £340,000 if all the shares are purchased in the warrant.

Tepnel applied to have the shares available for trading on the London Stock Exchange's AIM market on June 6.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.